Free Trial

David O. Watson Sells 5,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals logo with Medical background

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David O. Watson sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $19.55, for a total value of $97,750.00. Following the completion of the transaction, the general counsel owned 128,730 shares of the company's stock, valued at approximately $2,516,671.50. This represents a 3.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Apellis Pharmaceuticals Price Performance

NASDAQ APLS traded up $0.61 during trading hours on Tuesday, reaching $19.89. 1,883,887 shares of the company's stock were exchanged, compared to its average volume of 2,373,203. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62. The company's 50-day moving average is $18.26 and its two-hundred day moving average is $22.40. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $41.94.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same period in the prior year, the company earned ($0.54) earnings per share. The business's quarterly revenue was down 3.2% compared to the same quarter last year. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of APLS. GF Fund Management CO. LTD. increased its position in shares of Apellis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after acquiring an additional 573 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company's stock worth $84,000 after purchasing an additional 655 shares during the period. Xponance Inc. lifted its stake in Apellis Pharmaceuticals by 5.6% in the fourth quarter. Xponance Inc. now owns 14,072 shares of the company's stock valued at $449,000 after purchasing an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after purchasing an additional 758 shares during the period. Finally, Parallel Advisors LLC increased its position in Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock worth $33,000 after buying an additional 855 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on APLS shares. Robert W. Baird raised their price target on shares of Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an "outperform" rating in a research report on Friday. Bank of America lifted their target price on Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a "neutral" rating in a research note on Wednesday, July 16th. Wells Fargo & Company increased their price target on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Monday, June 2nd. Needham & Company LLC decreased their target price on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald began coverage on shares of Apellis Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $44.00 target price for the company. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $40.00.

Read Our Latest Analysis on Apellis Pharmaceuticals

About Apellis Pharmaceuticals

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Featured Articles

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?

Before you consider Apellis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.

While Apellis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines